Oclaro Names Pete Mangan New CFO


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Oclaro (NASDAQ: OCLR) today announced Pete Mangan, a 30-year technology finance veteran, has been appointed as chief financial officer (CFO), effective November 11, 2013.  Mangan, currently vice president, corporate finance for Oclaro, will succeed Jerry Turin, who previously announced plans to resign on November 8, 2013 to pursue other opportunities.  Mangan will report directly to Greg Dougherty, CEO. (Logo: http://photos.prnewswire.com/prnh/20130129/SF49903LOGO)"As vice president of corporate finance, Pete has been an instrumental leader in helping drive our restructuring plan," said Greg Dougherty, chief executive officer, Oclaro.  "His financial discipline and his wealth of experience in finance, restructuring and technology businesses are a strong complement to the executive team and we anticipate a seamless transition into his new role as CFO."Mr. Mangan joined Oclaro in May 2012 as vice president of corporate finance. Since joining the company he has been responsible for the global operations finance team and recently the corporate accounting and tax group.  Mr. Mangan brings Oclaro nearly 30 years of experience in a wide range of finance positions with leading companies including AMD, Trident Microsystems, FormFactor, Spansion, Asyst Technologies, and Sun Microsystems.  Mangan

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: NewsGuidanceOfferingsContractsFDAManagementGlobal